TDB backs indigenous 16-valent pneumococcal conjugate vaccine plant in Navi Mumbai
The Technology Development Board (TDB) of the Department of Science & Technology sanctioned financial support to TechInvention Lifecare Ltd, Navi Mumbai, to set up a commercial-scale cGMP facility for an indigenously developed 16-valent Pneumococcal Conjugate Vaccine (PCV-16), DST said on 21 November 2025.
Summary
The indigenous PCV-16 vaccine covers 16 pneumococcal serotypes; 13 overlap with existing global PCV platforms, and three emerging serotypes — 12F, 15A and 22F — have been added for broader coverage. Early development was done at TechInvention's facility in the BSC BioNEST Bio-Incubator, RCB Faridabad, and later at its 'HORIZON' R&D centre in Navi Mumbai. An Indian patent has been filed.
Key facts
- Support
- Technology Development Board (DST)
- Company
- TechInvention Lifecare Ltd, Navi Mumbai
- Vaccine
- 16-valent Pneumococcal Conjugate Vaccine (PCV-16)
- New serotypes
- 12F, 15A, 22F
- Facility
- Commercial-scale cGMP plant
Practice MCQs 2 questions
In November 2025, the Technology Development Board supported TechInvention Lifecare Ltd, Navi Mumbai, for commercial production of which indigenous vaccine?
Show answer
Correct answer: A — 16-valent Pneumococcal Conjugate Vaccine
TDB sanctioned support for a commercial-scale cGMP facility for the indigenous 16-valent Pneumococcal Conjugate Vaccine (PCV-16).
Which three emerging serotypes have been added in the indigenous PCV-16 vaccine beyond the 13 that overlap with existing global PCVs?
Show answer
Correct answer: B — 12F, 15A and 22F
The PCV-16 panel adds three emerging serotypes — 12F, 15A and 22F — for broader coverage.